

Laeq Malik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11747622/publications.pdf>

Version: 2024-02-01

13
papers

161
citations

1307594

7
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

272
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. <i>Frontiers in Immunology</i> , 2020, 11, 1228.	4.8	49
2	Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. <i>Cancer Science</i> , 2018, 109, 3383-3392.	3.9	28
3	Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3080.	4.1	15
4	Eligibility criteria for phase I clinical trials: tight vs loose?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 999-1002.	2.3	11
5	Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical Trials. <i>Cancer Investigation</i> , 2015, 33, 490-495.	1.3	10
6	How well informed is the informed consent for cancer clinical trials?. <i>Clinical Trials</i> , 2014, 11, 686-688.	1.6	9
7	Predicting success in regulatory approval from Phase I results. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1099-1103.	2.3	9
8	Increasing complexity in oncology phase I clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 519-523.	2.6	9
9	Association between tyrosine kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer. <i>Cancer Reports</i> , 2020, 3, e1275.	1.4	6
10	A comparison of the quality of informed consent for phase I oncology trials over a 30-year period. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 907-910.	2.3	5
11	Informed Consent for Phase I Oncology Trials: Form, Substance and Signature. <i>Journal of Clinical Medicine Research</i> , 2014, 6, 205-8.	1.2	5
12	Selective Targeting of Protein Kinase C (PKC)- δ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. <i>Cancers</i> , 2022, 14, 1596.	3.7	3
13	A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2